LAMECK SYMEKAH: Open Payments
NPI 1669143525 · GARLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,866 in 244 payments from 15 companies in 2025. Trend: 2023 $1,961 · 2024 $3,162 · 2025 $3,866
Food & beverage: $3,759Education: $107
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 29 | $594 |
| ABBVIE INC. | 50 | $560 |
| Neurocrine BioSciences, Inc. | 18 | $347 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $314 |
| Teva Pharmaceuticals USA, Inc. | 15 | $306 |
| Alkermes, Inc. | 16 | $273 |
| Axsome Therapeutics, Inc. | 13 | $272 |
| Otsuka America Pharmaceutical, Inc. | 19 | $247 |
| E.R. Squibb & Sons, L.L.C. | 18 | $226 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $209 |
Products named: FANAPT, VRAYLAR, INGREZZA, CAPLYTA, REXULTI, ARISTADA, Auvelity, COBENFY.
Industry payments across TX — which companies pay providers there.
